Skip to main content
. 2024 Sep 26;2024(9):CD006689. doi: 10.1002/14651858.CD006689.pub3

Comparison 9. Sulfadoxine‐pyrimethamine (SP) versus placebo.

Outcome or subgroup title No. of studies No. of participants Statistical method Effect size
9.1 Maternal peripheral parasitaemia at delivery (blood smear) 1 199 Risk Ratio (M‐H, Fixed, 95% CI) 0.27 [0.11, 0.67]
9.2 Maternal anaemia at delivery (packed cell volume <33%) 1 200 Risk Ratio (M‐H, Fixed, 95% CI) 0.94 [0.72, 1.23]
9.3 Maternal anaemia at delivery (< 120 g/L) 1 135 Risk Ratio (M‐H, Fixed, 95% CI) 0.95 [0.88, 1.03]
9.4 Placental malaria: acute infection (histology) 1   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
9.5 Placental malaria: chronic infection (histology) 1   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
9.6 Mean haemoglobin at delivery (in g/L) 1 135 Mean Difference (IV, Fixed, 95% CI) 3.38 [‐1.40, 8.15]
9.7 Low birth weight (< 2500 g) 1 208 Risk Ratio (M‐H, Fixed, 95% CI) 1.17 [0.63, 2.17]
9.8 Mean birth weight (in grams) 1 208 Mean Difference (IV, Fixed, 95% CI) ‐43.71 [‐253.05, 165.63]
9.9 Prematurity 1 208 Risk Ratio (M‐H, Fixed, 95% CI) 0.65 [0.20, 2.06]
9.10 Mother‐to‐child transmission of HIV 1 153 Risk Ratio (M‐H, Fixed, 95% CI) 0.89 [0.38, 2.06]
9.11 Maternal viral load at delivery (≥ 10 000 copies/mL) 1 81 Risk Ratio (M‐H, Fixed, 95% CI) 1.21 [0.48, 3.00]